Clinical trial
A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)
NCT03040401 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)
- Lead sponsor
- Vastra Gotaland Region
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- February 15, 2017
- Completion date
- December 15, 2019
- Enrollment
- 15 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.